 | • レポートコード：20QY06-00904 • 出版社/出版日：QYResearch / 2020年6月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、133ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、インフリキシマブ・バイオシミラーのグローバル市場について種類別（インフリキシマブ、インフリキシマブ-dyyb、インフリキシマブ-アブダ）、用途別（クローン病、小児クローン病、潰瘍性大腸炎、関節リウマチ、強直性脊椎炎、乾癬性関節炎、尋常性乾癬）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・インフリキシマブ・バイオシミラー市場の概要 ・世界の主要地域別インフリキシマブ・バイオシミラー市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界のインフリキシマブ・バイオシミラー市場規模2015-2026：種類別（インフリキシマブ、インフリキシマブ-dyyb、インフリキシマブ-アブダ） ・世界のインフリキシマブ・バイオシミラー市場規模2015-2026：用途別（クローン病、小児クローン病、潰瘍性大腸炎、関節リウマチ、強直性脊椎炎、乾癬性関節炎、尋常性乾癬） ・インフリキシマブ・バイオシミラーの北米市場規模2015-2020 ・インフリキシマブ・バイオシミラーのヨーロッパ市場規模2015-2020 ・インフリキシマブ・バイオシミラーの中国市場規模2015-2020 ・インフリキシマブ・バイオシミラーの日本市場規模2015-2020 ・インフリキシマブ・バイオシミラーの東南アジア市場規模2015-2020 ・インフリキシマブ・バイオシミラーのインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Janssen Biotech、Merck and Co.、Pfizer） ・インフリキシマブ・バイオシミラーの製造コスト分析 ・販売チャネル、流通業者、顧客 ・インフリキシマブ・バイオシミラーの市場動向・機会・課題 ・調査の結論 |
Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.
Market Analysis and Insights: Global Infliximab and biosimilar Market
The global Infliximab and biosimilar market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026.
Global Infliximab and biosimilar Scope and Market Size
The global Infliximab and biosimilar market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Infliximab and biosimilar market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Infliximab and biosimilar market is segmented into
Infliximab
infliximab-dyyb
infliximab-abda
Segment by Application, the Infliximab and biosimilar market is segmented into
Crohn’s Disease
Pediatric Crohn’s Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis
The Infliximab and biosimilar market is analysed and market size information is provided by regions (countries). Segment by Application, the Infliximab and biosimilar market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Infliximab and biosimilar Market Share Analysis
Infliximab and biosimilar market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Infliximab and biosimilar business, the date to enter into the Infliximab and biosimilar market, Infliximab and biosimilar product introduction, recent developments, etc.
The major vendors covered:
Janssen Biotech
Merck and Co.
Pfizer
…
Table of Contents
1 Infliximab and biosimilar Market Overview
1.1 Infliximab and biosimilar Product Scope
1.2 Infliximab and biosimilar Segment by Type
1.2.1 Global Infliximab and biosimilar Sales by Type (2020-2026)
1.2.2 Infliximab
1.2.3 infliximab-dyyb
1.2.4 infliximab-abda
1.3 Infliximab and biosimilar Segment by Application
1.3.1 Global Infliximab and biosimilar Sales Comparison by Application (2020-2026)
1.3.2 Crohn’s Disease
1.3.3 Pediatric Crohn’s Disease
1.3.4 Ulcerative Colitis
1.3.5 Rheumatoid Arthritis
1.3.6 Ankylosing Spondylitis
1.3.7 Psoriatic Arthritis
1.3.8 Plaque Psoriasis
1.4 Infliximab and biosimilar Market Estimates and Forecasts (2015-2026)
1.4.1 Global Infliximab and biosimilar Sales Growth Rate (2015-2026)
1.4.2 Global Infliximab and biosimilar Revenue and Growth Rate (2015-2026)
1.4.3 Global Infliximab and biosimilar Price Trends (2015-2026)
2 Infliximab and biosimilar Estimate and Forecast by Region
2.1 Global Infliximab and biosimilar Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Infliximab and biosimilar Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Infliximab and biosimilar Sales Market Share by Region (2015-2020)
2.2.2 Global Infliximab and biosimilar Revenue Market Share by Region (2015-2020)
2.3 Global Infliximab and biosimilar Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Infliximab and biosimilar Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Infliximab and biosimilar Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Infliximab and biosimilar Estimates and Projections (2015-2026)
2.4.2 Europe Infliximab and biosimilar Estimates and Projections (2015-2026)
2.4.3 China Infliximab and biosimilar Estimates and Projections (2015-2026)
2.4.4 Japan Infliximab and biosimilar Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Infliximab and biosimilar Estimates and Projections (2015-2026)
2.4.6 India Infliximab and biosimilar Estimates and Projections (2015-2026)
3 Global Infliximab and biosimilar Competition Landscape by Players
3.1 Global Top Infliximab and biosimilar Players by Sales (2015-2020)
3.2 Global Top Infliximab and biosimilar Players by Revenue (2015-2020)
3.3 Global Infliximab and biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Infliximab and biosimilar as of 2019)
3.4 Global Infliximab and biosimilar Average Price by Company (2015-2020)
3.5 Manufacturers Infliximab and biosimilar Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Infliximab and biosimilar Players (Opinion Leaders)
4 Global Infliximab and biosimilar Market Size by Type
4.1 Global Infliximab and biosimilar Historic Market Review by Type (2015-2020)
4.1.1 Global Infliximab and biosimilar Sales Market Share by Type (2015-2020)
4.1.2 Global Infliximab and biosimilar Revenue Market Share by Type (2015-2020)
4.1.3 Global Infliximab and biosimilar Price by Type (2014-2020)
4.2 Global Infliximab and biosimilar Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Infliximab and biosimilar Sales Forecast by Type (2021-2026)
4.2.2 Global Infliximab and biosimilar Revenue Forecast by Type (2021-2026)
4.2.3 Global Infliximab and biosimilar Price Forecast by Type (2021-2026)
5 Global Infliximab and biosimilar Market Size by Application
5.1 Global Infliximab and biosimilar Historic Market Review by Application (2015-2020)
5.1.1 Global Infliximab and biosimilar Sales Market Share by Application (2015-2020)
5.1.2 Global Infliximab and biosimilar Revenue Market Share by Application (2015-2020)
5.1.3 Global Infliximab and biosimilar Price by Application (2015-2020)
5.2 Global Infliximab and biosimilar Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Infliximab and biosimilar Sales Forecast by Application (2021-2026)
5.2.2 Global Infliximab and biosimilar Revenue Forecast by Application (2021-2026)
5.2.3 Global Infliximab and biosimilar Price Forecast by Application (2021-2026)
3 North America Infliximab and biosimilar Market Facts & Figures
3.2 North America Infliximab and biosimilar Sales Market Share by Company (2015-2020)
3.3 North America Infliximab and biosimilar Sales Market Share by Type (2015-2020)
3.4 North America Infliximab and biosimilar Sales Market Share by Application (2015-2020)
4 Europe Infliximab and biosimilar Market Facts & Figures
4.2 Europe Infliximab and biosimilar Sales Market Share by Company (2015-2020)
4.3 Europe Infliximab and biosimilar Sales Market Share by Type (2015-2020)
4.4 Europe Infliximab and biosimilar Sales Market Share by Application (2015-2020)
5 China Infliximab and biosimilar Market Facts & Figures
5.2 China Infliximab and biosimilar Sales Market Share by Company (2015-2020)
5.3 China Infliximab and biosimilar Sales Market Share by Type (2015-2020)
5.4 China Infliximab and biosimilar Sales Market Share by Application (2015-2020)
6 Japan Infliximab and biosimilar Market Facts & Figures
6.2 Japan Infliximab and biosimilar Sales Market Share by Company (2015-2020)
6.3 Japan Infliximab and biosimilar Sales Market Share by Type (2015-2020)
6.4 Japan Infliximab and biosimilar Sales Market Share by Application (2015-2020)
7 Southeast Asia Infliximab and biosimilar Market Facts & Figures
7.2 Southeast Asia Infliximab and biosimilar Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Infliximab and biosimilar Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Infliximab and biosimilar Sales Market Share by Application (2015-2020)
8 India Infliximab and biosimilar Market Facts & Figures
8.2 India Infliximab and biosimilar Sales Market Share by Company (2015-2020)
8.3 India Infliximab and biosimilar Sales Market Share by Type (2015-2020)
8.4 India Infliximab and biosimilar Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Infliximab and biosimilar Business
12.1 Janssen Biotech
12.1.1 Janssen Biotech Infliximab and biosimilar Corporation Information
12.1.2 Janssen Biotech Infliximab and biosimilar Business Overview and Total Revenue
12.1.3 Janssen Biotech Infliximab and biosimilar Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Janssen Biotech Infliximab and biosimilar Products Offered
12.1.5 Janssen Biotech Recent Development
12.2 Merck and Co.
12.2.1 Merck and Co. Infliximab and biosimilar Corporation Information
12.2.2 Merck and Co. Infliximab and biosimilar Business Overview and Total Revenue
12.2.3 Merck and Co. Infliximab and biosimilar Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Merck and Co. Infliximab and biosimilar Products Offered
12.2.5 Merck and Co. Recent Development
12.3 Pfizer
12.3.1 Pfizer Infliximab and biosimilar Corporation Information
12.3.2 Pfizer Infliximab and biosimilar Business Overview and Total Revenue
12.3.3 Pfizer Infliximab and biosimilar Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Pfizer Infliximab and biosimilar Products Offered
12.3.5 Pfizer Recent Development
…
13 Infliximab and biosimilar Manufacturing Cost Analysis
13.1 Infliximab and biosimilar Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Infliximab and biosimilar
13.4 Infliximab and biosimilar Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Infliximab and biosimilar Distributors List
14.3 Infliximab and biosimilar Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Infliximab and biosimilar Sales (K MT) Growth Rate by Type (2020-2026)
Table 2. Global Infliximab and biosimilar Sales (K MT) Comparison by Application (2020-2026)
Table 3. Global Market Infliximab and biosimilar Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Infliximab and biosimilar Sales (K MT) by Region (2015-2020)
Table 5. Global Infliximab and biosimilar Sales Market Share by Region (2015-2020)
Table 6. Global Infliximab and biosimilar Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Infliximab and biosimilar Revenue Share by Region (2015-2020)
Table 8. Global Infliximab and biosimilar Sales (K MT) Forecast by Region (2021-2026)
Table 9. Global Infliximab and biosimilar Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Infliximab and biosimilar Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Infliximab and biosimilar Revenue Share Forecast by Region (2021-2026)
Table 12. Global Infliximab and biosimilar (K MT) of Key Companies (2015-2020)
Table 13. Global Infliximab and biosimilar Sales Share by Company (2015-2020)
Table 14. Global Infliximab and biosimilar Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Infliximab and biosimilar Revenue Share by Company (2015-2020)
Table 16. Global Infliximab and biosimilar by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Infliximab and biosimilar as of 2019)
Table 17. Global Infliximab and biosimilar Average Price (USD/MT) of Key Company (2015-2020)
Table 18. Manufacturers Infliximab and biosimilar Manufacturing Sites and Area Served
Table 19. Manufacturers Infliximab and biosimilar Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Infliximab and biosimilar Players
Table 22. Global Infliximab and biosimilar Sales (K MT) by Type (2015-2020)
Table 23. Global Infliximab and biosimilar Sales Share by Type (2015-2020)
Table 24. Global Infliximab and biosimilar Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Infliximab and biosimilar Price (K MT) by Type (2015-2020)
Table 26. Global Infliximab and biosimilar Sales Share by Type (2021-2026)
Table 27. Global Infliximab and biosimilar Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Infliximab and biosimilar Revenue Share by Type (2021-2026)
Table 29. Global Infliximab and biosimilar Price (K MT) by Type (2021-2026)
Table 30. Global Infliximab and biosimilar Sales (K MT) by Application (2015-2020)
Table 31. Global Infliximab and biosimilar Sales Share by Application (2015-2020)
Table 32. Global Infliximab and biosimilar Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Infliximab and biosimilar Price (K MT) by Application (2015-2020)
Table 34. Global Infliximab and biosimilar Sales (K MT) by Application (2021-2026)
Table 35. Global Infliximab and biosimilar Sales Share by Application (2021-2026)
Table 36. Global Infliximab and biosimilar Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Infliximab and biosimilar Revenue Share by Application (2021-2026)
Table 38. Global Infliximab and biosimilar Price (K MT) by Application (2021-2026)
Table 39. United States Infliximab and biosimilar Sales (K MT) by Company (2015-2020)
Table 40. United States Infliximab and biosimilar Sales Market Share by Company (2015-2020)
Table 41. United States Infliximab and biosimilar Sales (K MT) by Type (2015-2020)
Table 42. United States Infliximab and biosimilar Sales Market Share by Type (2015-2020)
Table 43. United States Infliximab and biosimilar Sales (K MT) by Application (2015-2020)
Table 44. United States Infliximab and biosimilar Sales Market Share by Application (2015-2020)
Table 45. Europe Infliximab and biosimilar Sales (K MT) by Company (2015-2020)
Table 46. Europe Infliximab and biosimilar Sales Market Share by Company (2015-2020)
Table 47. Europe Infliximab and biosimilar Sales (K MT) by Type (2015-2020)
Table 48. Europe Infliximab and biosimilar Sales Market Share by Type (2015-2020)
Table 49. Europe Infliximab and biosimilar Sales (K MT) by Application (2015-2020)
Table 50. Europe Infliximab and biosimilar Sales Market Share by Type (2015-2020)
Table 51. China Infliximab and biosimilar Sales (K MT) by Company (2015-2020)
Table 52. China Infliximab and biosimilar Sales Market Share by Company (2015-2020)
Table 53. China Infliximab and biosimilar Sales (K MT) by Type (2015-2020)
Table 54. China Infliximab and biosimilar Sales Market Share by Type (2015-2020)
Table 55. China Infliximab and biosimilar Sales (K MT) by Application (2015-2020)
Table 56. China Infliximab and biosimilar Sales Market Share by Application (2015-2020)
Table 57. Japan Infliximab and biosimilar Sales (K MT) by Company (2015-2020)
Table 58. Japan Infliximab and biosimilar Sales Market Share by Company (2015-2020)
Table 59. Japan Infliximab and biosimilar Sales (K MT) by Type (2015-2020)
Table 60. Japan Infliximab and biosimilar Sales Market Share by Type (2015-2020)
Table 61. Japan Infliximab and biosimilar Sales (K MT) by Application (2015-2020)
Table 62. Japan Infliximab and biosimilar Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Infliximab and biosimilar Sales (K MT) by Company (2015-2020)
Table 64. Southeast Asia Infliximab and biosimilar Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Infliximab and biosimilar Sales (K MT) by Type (2015-2020)
Table 66. Southeast Asia Infliximab and biosimilar Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Infliximab and biosimilar Sales (K MT) by Type (2015-2020)
Table 68. Southeast Asia Infliximab and biosimilar Sales Market Share by Application (2015-2020)
Table 69. India Infliximab and biosimilar Sales (K MT) by Company (2015-2020)
Table 70. India Infliximab and biosimilar Sales Market Share by Company (2015-2020)
Table 71. India Infliximab and biosimilar Sales (K MT) by Type (2015-2020)
Table 72. India Infliximab and biosimilar Sales Market Share by Type (2015-2020)
Table 73. India Infliximab and biosimilar Sales (K MT) by Application (2015-2020)
Table 74. India Infliximab and biosimilar Sales Market Share by Application (2015-2020)
Table 75. Janssen Biotech Corporation Information
Table 76. Janssen Biotech Description and Business Overview
Table 77. Janssen Biotech Infliximab and biosimilar Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 78. Janssen Biotech Infliximab and biosimilar Product
Table 79. Janssen Biotech Recent Development
Table 80. Merck and Co. Corporation Information
Table 81. Merck and Co. Description and Business Overview
Table 82. Merck and Co. Infliximab and biosimilar Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 83. Merck and Co. Infliximab and biosimilar Product
Table 84. Merck and Co. Recent Development
Table 85. Pfizer Corporation Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Infliximab and biosimilar Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 88. Pfizer Infliximab and biosimilar Product
Table 89. Pfizer Recent Development
Table 90. Production Base and Market Concentration Rate of Raw Material
Table 91. Key Suppliers of Raw Materials
Table 92. Infliximab and biosimilar Distributors List
Table 93. Infliximab and biosimilar Customers List
Table 94. Market Key Trends
Table 95. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 96. Key Challenges
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Infliximab and biosimilar Product Picture
Figure 2. Global Infliximab and biosimilar Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Infliximab and biosimilar Market Share by Application in 2020 & 2026
Figure 6. Crohn's Disease Examples
Figure 7. Pediatric Crohn's Disease Examples
Figure 8. Ulcerative Colitis Examples
Figure 9. Rheumatoid Arthritis Examples
Figure 10. Ankylosing Spondylitis Examples
Figure 11. Psoriatic Arthritis Examples
Figure 12. Plaque Psoriasis Examples
Figure 13. Global Infliximab and biosimilar Sales (K MT) Growth Rate (2015-2026)
Figure 14. Global Infliximab and biosimilar Revenue (US$ Million) Growth Rate (2015-2026)
Figure 15. Global Infliximab and biosimilar Price Trends Growth Rate (2015-2026) (USD/MT)
Figure 16. Global Infliximab and biosimilar Revenue Market Share by Region: 2015 VS 2020
Figure 17. Global Infliximab and biosimilar Revenue Market Share by Region: 2021 VS 2026
Figure 18. United States Infliximab and biosimilar Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. United States Infliximab and biosimilar Sales (K MT) Growth Rate (2015-2026)
Figure 20. Europe Infliximab and biosimilar Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Europe Infliximab and biosimilar Sales (Million USD) Growth Rate (2015-2026)
Figure 22. China Infliximab and biosimilar Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. China Infliximab and biosimilar Sales (Million USD) and Growth Rate (2015-2026)
Figure 24. Japan Infliximab and biosimilar Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. Japan Infliximab and biosimilar Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Southeast Asia Infliximab and biosimilar Revenue (Million USD) Growth Rate (2015-2026)
Figure 27. Southeast Asia Infliximab and biosimilar Sales (Million USD) Growth Rate (2015-2026)
Figure 28. India Infliximab and biosimilar Revenue (Million USD) Growth Rate (2015-2026)
Figure 29. India Infliximab and biosimilar Sales (Million USD) Growth Rate (2015-2026)
Figure 30. Global 5 Largest Infliximab and biosimilar Players Market Share by Revenue in Infliximab and biosimilar 2015 & 2019
Figure 31. Infliximab and biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 32. Global Infliximab and biosimilar Revenue Share by Type (2015-2020)
Figure 33. Global Infliximab and biosimilar Revenue Growth Rate by Type in 2015 & 2019
Figure 34. Global Infliximab and biosimilar Revenue Share by Application (2015-2020)
Figure 35. Global Infliximab and biosimilar Revenue Growth Rate by Application in 2015 & 2019
Figure 36. United States Infliximab and biosimilar Sales Market Share by Type in 2019
Figure 37. United States Infliximab and biosimilar Sales Market Share by Type in 2019
Figure 38. Europe Infliximab and biosimilar Sales Market Share by Company in 2019
Figure 39. Europe Infliximab and biosimilar Sales Market Share by Type in 2019
Figure 40. Europe Infliximab and biosimilar Sales Market Share by Application in 2019
Figure 41. China Infliximab and biosimilar Sales Market Share by Company in 2019
Figure 42. China Infliximab and biosimilar Sales Market Share by Type in 2019
Figure 43. China Infliximab and biosimilar Sales Market Share by Application in 2019
Figure 44. Japan Infliximab and biosimilar Sales Market Share by Company in 2019
Figure 45. Japan Infliximab and biosimilar Sales Market Share by Type in 2019
Figure 46. Japan Infliximab and biosimilar Sales Market Share by Application in 2019
Figure 47. Southeast Asia Infliximab and biosimilar Sales Market Share by Company in 2019
Figure 48. Southeast Asia Infliximab and biosimilar Sales Market Share by Type in 2019
Figure 49. Southeast Asia Infliximab and biosimilar Sales Market Share by Application in 2019
Figure 50. India Infliximab and biosimilar Sales Market Share by Company in 2019
Figure 51. India Infliximab and biosimilar Sales Market Share by Type in 2019
Figure 52. India Infliximab and biosimilar Sales Market Share by Application in 2019
Figure 53. Janssen Biotech Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Merck and Co. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Key Raw Materials Price Trend
Figure 57. Manufacturing Cost Structure of Infliximab and biosimilar
Figure 58. Manufacturing Process Analysis of Infliximab and biosimilar
Figure 59. Infliximab and biosimilar Industrial Chain Analysis
Figure 60. Channels of Distribution
Figure 61. Distributors Profiles
Figure 62. Porter's Five Forces Analysis
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
バイオシミラー薬物の世界市場レポート2020 A recently published report by QY Research titled Global Biosimilar Drug Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate da…- バイオシミラーインスリンの世界市場レポート2020 Market Analysis and Insights: Global Biosimilar Insulin Market The global Biosimilar Insulin market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global Biosimilar Insulin Scope and Market Size The global Biosimilar …
- インターフェロンアルファ-2aバイオシミラーの世界市場レポート2020 Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplasti…
- 神経バイオシミラー生物製品の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Nerve Biosimilar Biological Products market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Nerve Bi…
- バイオシミラーインスリンの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Biosimilar Insulin market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Biosimilar Insulin market …